Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;7(Suppl 1):S35.
doi: 10.21037/atm.2019.02.13.

When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?

Jun Gong  1 , Joseph Chao  2
Affiliations
Editorial

When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?

Jun Gong et al. Ann Transl Med. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: J Chao has served as a consult/advisor for Lilly Oncology, Merck, Foundation Medicine, Astra-Zeneca, Boston Biomedical, Daiichi-Sankyo, and Taiho. J Chao also serves on the Speakers Bureau and has received research support (institutional) from Merck. J Gong has no conflicts of interest to declare.

Comment on

References

    1. Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. Oncologist 2019;24:103-9. 10.1634/theoncologist.2018-0221 - DOI - PMC - PubMed
    1. Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013. 10.1001/jamaoncol.2018.0013 - DOI - PMC - PubMed
    1. Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018;392:123-33. 10.1016/S0140-6736(18)31257-1 - DOI - PubMed
    1. Boyiadzis MM, Kirkwood JM, Marshall JL, et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer 2018;6:35. 10.1186/s40425-018-0342-x - DOI - PMC - PubMed
    1. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9. 10.1038/nature13480 - DOI - PMC - PubMed